ATLANTA, GA – Galectin Therapeutics will move its headquarters to Norcross, Ga., on Oct. 1 to be nearer the Complex Carbohydrate Research Center at The University of Georgia.
The company, currently in Newton, Mass., said it will keep a lab presence in Natick, Mass. Galectin (NASDAQ: GALT) develops therapeutics that target galectin proteins to treat fibrosis and cancer.
Its new headquarters will be in Northwoods Commons at 4960 Peachtree Industrial Boulevard.
“This move and reorganization of the company will allow continued utilization of the excellent environment for biotechnology in the Boston area while taking advantage of the robust and collaborative research and clinical assets in the Atlanta area,” saidHarold Shlevin, incoming chief operating officer of Galectin Therapeutics, in a statement. “My networks in the local lifescience industry will help foster the Company’s connections within the business and research community that drive new product development and business expansion.”